UNICEF raises Panacea Biotec pentavalent vaccine award by about Rs 80 Crore
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 14.3 pts more than Nifty Microcap 250 and 14.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Panacea Biotec received an amended UNICEF award for its pentavalent vaccine Easyfive-TT, adding about US$ 8.93 million (roughly Rs 80 Crore). This includes value increases of about Rs 23 Crore for 2026 and Rs 24 Crore for 2027, plus an additional Rs 33 Crore award for 2027. The original supply contract with the UN agency ran from 2023 to 2027, and this amendment strengthens the company's export order book for those years.
Strengthens revenue visibility from UNICEF vaccine exports in US dollars for 2026-2027, boosting the order book for Easyfive-TT.